>Immunity from prior-infection was worse than vaccination at protecting people from Delta.[1]
Now you are saying :
>We literally don't have the evidence needed to say with certainty that infection (of all levels of severity) provides "an immunity just as good as vaccination."
Meanwhile, all the data coming out of countries with centralized covid tracking suggests natural immunity is as good or better.
Reviewing health data for 2.5 million Israelis, It found:
>SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021
>Conclusions This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.
First you said:
>Immunity from prior-infection was worse than vaccination at protecting people from Delta.[1]
Now you are saying :
>We literally don't have the evidence needed to say with certainty that infection (of all levels of severity) provides "an immunity just as good as vaccination."
Meanwhile, all the data coming out of countries with centralized covid tracking suggests natural immunity is as good or better.
Here is another link if you are interested: https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v...
Reviewing health data for 2.5 million Israelis, It found:
>SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021
>Conclusions This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.